

Robert S Brown

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6329077/robert-s-brown-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

183
papers

9,801
citations

46
h-index

98
g-index

212
ext. papers

12,203
ext. citations

7.6
avg, IF

6.1
L-index

#	Paper	IF	Citations
183	Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants.. <i>American Journal of Transplantation</i> , 2022 ,	8.7	6
182	One-Year Outcomes of the Multi-Center Study to Transplant Hepatitis C-Infected kidneys (MYTHIC) Trial.. <i>Kidney International Reports</i> , 2022 , 7, 241-250	4.1	0
181	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH).. <i>Liver International</i> , 2022 ,	7.9	1
180	Optimizing pre-donation physiologic evaluation for enhanced recovery after living liver donation - Systematic review and multidisciplinary expert panel recommendations.. <i>Clinical Transplantation</i> , 2022 , e14680	3.8	0
179	Sociodemographic characteristics of living liver donors: Few changes over 20 years.. <i>Clinical Transplantation</i> , 2022 , e14701	3.8	
178	Hepatology Highlights. <i>Hepatology</i> , 2021 , 74, 2931-2934	11.2	
177	Hepatology Highlights. <i>Hepatology</i> , 2021 , 74, 2329-2332	11.2	
176	Identification of Quantifiable Predictors of Relapse in Patients with Alcohol-Associated Liver Disease. <i>Hepatology Communications</i> , 2021 , 5, 1156-1164	6	1
175	Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag. <i>JHEP Reports</i> , 2021 , 3, 100228	10.3	2
174	Hepatology Highlights. <i>Hepatology</i> , 2021 , 73, 1245-1247	11.2	
173	Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1051-1057.e2	6.9	30
172	Hepatology Highlights. <i>Hepatology</i> , 2021 , 73, 2085-2088	11.2	0
171	Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients. <i>Clinical Transplantation</i> , 2021 ,	3.8	1
170	Dynamic α -fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2021 , 156, 559-567	5.4	2
169	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. <i>Journal of Hepatology</i> , 2021 , 75, 1026-1033	13.4	3
168	Can Living Donor Liver Transplantation in the United States Reach Its Potential?. <i>Liver Transplantation</i> , 2021 , 27, 1644-1652	4.5	1
167	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol-Associated Hepatitis. <i>Liver Transplantation</i> , 2021 , 27, 1382-1391	4.5	0

166	Association Between Kidney Dysfunction Types and Mortality Among Hospitalized Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	0
165	Uncontrolled diabetes mellitus increases risk of infection in patients with advanced cirrhosis. <i>Digestive and Liver Disease</i> , 2021 , 53, 445-451	3.3	4
164	Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastropasty. <i>Gastrointestinal Endoscopy</i> , 2021 , 93, 1110-1118	5.2	12
163	SARS-CoV-2 infection increases tacrolimus concentrations in solid-organ transplant recipients. <i>Clinical Transplantation</i> , 2021 , 35, e14193	3.8	3
162	National Trends in Location of Death in Patients With End-Stage Liver Disease. <i>Liver Transplantation</i> , 2021 , 27, 165-176	4.5	3
161	A Review of the Current State of Liver Transplantation Disparities. <i>Liver Transplantation</i> , 2021 , 27, 434-443	4.5	10
160	Hepatology Highlights. <i>Hepatology</i> , 2021 , 73, 1-3	11.2	
159	Hepatology Highlights. <i>Hepatology</i> , 2021 , 73, 475-478	11.2	
158	Reply. <i>Liver Transplantation</i> , 2021 , 27, 606	4.5	
157	Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes. <i>American Journal of Medicine</i> , 2021 , 134, 1330-1338	2.4	0
156	Medicaid Expansion Association With End-Stage Liver Disease Mortality Depends on Leniency of Medicaid Hepatitis C Virus Coverage. <i>Liver Transplantation</i> , 2021 , 27, 1723-1732	4.5	0
155	The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin. <i>Liver Transplantation</i> , 2021 , 27, 1191-1202	4.5	1
154	Hepatology Highlights. <i>Hepatology</i> , 2021 , 74, 1-4	11.2	2
153	Hepatology Highlights. <i>Hepatology</i> , 2021 , 74, 539-542	11.2	
152	Mortality, sepsis, and organ failure in hospitalized patients with cirrhosis vary by type of infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 ,	4	2
151	Hepatology Highlights. <i>Hepatology</i> , 2021 , 74, 1137-1140	11.2	
150	Hepatology Highlights. <i>Hepatology</i> , 2021 , 74, 1727-1729	11.2	
149	Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States. <i>Hepatology</i> , 2021 , 74, 1523-1532	11.2	7

148	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
147	Hepatology Highlights. <i>Hepatology</i> , 2020 , 72, 1893-1896	11.2	
146	Hepatology Highlights. <i>Hepatology</i> , 2020 , 72, 1505-1508	11.2	
145	Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. <i>Liver Transplantation</i> , 2020 , 26, 1328-1336	4.5	3
144	Hepatology Highlights. <i>Hepatology</i> , 2020 , 71, 771-773	11.2	
143	Cholangiocarcinoma: Diagnosis and Management. <i>Clinics in Liver Disease</i> , 2020 , 24, 421-436	4.6	7
142	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020 , 72, 2182-2196	11.2	29
141	Hepatology Highlights. <i>Hepatology</i> , 2020 , 71, 405-407	11.2	
140	Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study. <i>Cancer Causes and Control</i> , 2020 , 31, 321-332	2.8	10
139	Hepatology Highlights. <i>Hepatology</i> , 2020 , 71, 1-3	11.2	1
138	Hepatology Highlights. <i>Hepatology</i> , 2020 , 71, 1527-1529	11.2	
137	Hepatology Highlights. <i>Hepatology</i> , 2020 , 71, 1143-1145	11.2	
136	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. <i>American Journal of Transplantation</i> , 2020 , 20, 1800-1808	8.7	474
135	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020 , 40, 1841-1852	7.9	28
134	Development and external validation of a prediction risk model for short-term mortality among hospitalized U.S. COVID-19 patients: A proposal for the COVID-AID risk tool. <i>PLoS ONE</i> , 2020 , 15, e0239536	3.7	22
133	Association of Search Query Interest in Gastrointestinal Symptoms With COVID-19 Diagnosis in the United States: Infodemiology Study. <i>JMIR Public Health and Surveillance</i> , 2020 , 6, e19354	11.4	15
132	Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. <i>Journal of Hepatology</i> , 2020 , 72, 441-449	13.4	60
131	Patient Perspectives of High-Quality Care on the Liver Transplant Waiting List: A Qualitative Study. <i>Liver Transplantation</i> , 2020 , 26, 238-246	4.5	2

130	The North American Consortium for the Study of End-Stage Liver Disease-Acute-on-Chronic Liver Failure Score Accurately Predicts Survival: An External Validation Using a National Cohort. <i>Liver Transplantation</i> , 2020 , 26, 187-195	4.5	12
129	Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. <i>Transplantation</i> , 2020 , 104, 476-481	1.8	13
128	Hepatology Highlights. <i>Hepatology</i> , 2020 , 72, 791-793	11.2	
127	Quality improvement initiative increases total paracentesis and early paracentesis rates in hospitalised cirrhotics with ascites. <i>Frontline Gastroenterology</i> , 2020 , 11, 22-27	2.6	2
126	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2678-2687	12.7	28
125	Hepatology Highlights. <i>Hepatology</i> , 2020 , 72, 369-370	11.2	
124	Evaluation of Alcohol Taxes as a Public Health Opportunity to Reduce Liver Transplant Listings for Alcohol-Related Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020 , 44, 2307-2315	3.7	1
123	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020 , 71, 522-538	11.2	71
122	Utilization of Hepatitis C Virus (HCV)-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?. <i>Hepatology</i> , 2020 , 71, 4-7	11.2	6
121	Details Make the Difference: The Important Need to Accurately Understand the Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunts in Patients with Ascites. <i>Journal of Vascular and Interventional Radiology</i> , 2019 , 30, 1310-1311	2.4	
120	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 469-472	11.2	
119	Peripartum Maternal Hepatitis B Care in a US Nationwide Data Set. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, e424-e430	3	2
118	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 2311-2314	11.2	1
117	Acute HCV Treatment: What Should We Do in the DAA Era?. <i>Current Hepatology Reports</i> , 2019 , 18, 216-221		
116	Management of Thrombocytopenia in Patients with Chronic Liver Disease. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 2757-2768	4	21
115	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 1365-1368	11.2	
114	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 1849-1851	11.2	
113	A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol-Related Liver Disease. <i>Hepatology</i> , 2019 , 70, 1038-1044	11.2	11

112	Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. <i>Current Hepatology Reports</i> , 2019 , 18, 363-369	1	
111	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , 2019 , 3, 1388-1399	6	5
110	Hepatology Highlights. <i>Hepatology</i> , 2019 , 70, 1497-1499	11.2	1
109	The clinical and economic burden of patients with chronic liver disease and thrombocytopenia receiving platelet transfusions during planned invasive procedures. <i>GastroHep</i> , 2019 , 1, 236-248	1	3
108	Genetic Causes of Liver Disease: When to Suspect a Genetic Etiology, Initial Lab Testing, and the Basics of Management. <i>Medical Clinics of North America</i> , 2019 , 103, 991-1003	7	4
107	Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the United States.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 424-424	2.2	
106	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 927-930	11.2	
105	Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Liver Transplantation</i> , 2019 , 25, 1155-1164	4.5	10
104	IDDF2019-ABS-0210 Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1B infection and compensated cirrhosis: the EXPEDITION-8 study 2019 ,		7
103	Hepatology Highlights. <i>Hepatology</i> , 2019 , 70, 1881-1884	11.2	
102	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019 , 575, 505-511	50.4	245
101	Early Paracentesis in High-Risk Hospitalized Patients: Time for a New Quality Indicator. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1863-1869	0.7	8
100	Cirrhosis as a Comorbidity in Conditions Subject to the Hospital Readmissions Reduction Program. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1488-1495	0.7	7
99	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 1-4	11.2	1
98	Hepatology Highlights. <i>Hepatology</i> , 2018 , 67, 817-819	11.2	
97	Peripartum Care for Mothers Diagnosed with Hepatitis B During Pregnancy: A Survey of Provider Practices. <i>Maternal and Child Health Journal</i> , 2018 , 22, 1345-1351	2.4	4
96	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018 , 68, 1298-1307	11.2	121
95	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018 , 69, 396-405	40.4	83

94	Hepatology Highlights. <i>Hepatology</i> , 2018 , 67, 1647-1650	11.2	
93	Hepatology Highlights. <i>Hepatology</i> , 2018 , 67, 1195-1197	11.2	
92	Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1503-1510.e3	6.9	9
91	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i> , 2018 , 67, 1560-1599	11.2	1460
90	Liver atrophy and regeneration in noncirrhotic portal vein thrombosis: Effect of surgical shunts. <i>Liver Transplantation</i> , 2018 , 24, 881-887	4.5	6
89	Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. <i>Hepatology Communications</i> , 2018 , 2, 354-363	6	9
88	Nonviral or Drug-Induced Etiologies of Acute Liver Failure. <i>Clinics in Liver Disease</i> , 2018 , 22, 347-360	4.6	6
87	Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. <i>Liver International</i> , 2018 , 38, 1010-1021	7.9	8
86	Hepatitis C and Liver Transplantation in the Era of New Antiviral Treatments 2018 , 239-262		
85	Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. <i>Liver Transplantation</i> , 2018 , 24, 380-393	4.5	67
84	Geographic Areas of Liver Distribution in the United States Should Not Be Redesignated According to the 2016 Eight-District Organ Procurement and Transplantation Network Proposal. <i>Clinical Liver Disease</i> , 2018 , 12, 65-67	2.2	
83	Critical Care Management of Gastrointestinal Bleeding and Ascites in Liver Failure. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018 , 39, 566-577	3.9	1
82	Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction. <i>Clinical Transplantation</i> , 2018 , 32, e13415	3.8	6
81	Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. <i>Clinical Liver Disease</i> , 2018 , 12, 33-34	2.2	95
80	Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. <i>Annals of Surgery</i> , 2018 , 268, 690-699	7.8	46
79	American Gastroenterological Association Institute Technical Review on Initial Testing and Management of Acute Liver Disease. <i>Gastroenterology</i> , 2017 , 152, 648-664.e5	13.3	9
78	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. <i>Hepatology</i> , 2017 , 66, 1090-1101	11.2	127
77	Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. <i>Transplant International</i> , 2017 , 30, 196-208	3	12

76	Treatment of hepatitis C virus in advanced renal disease. <i>Clinical Liver Disease</i> , 2017 , 10, 79-81	2.2	
75	Genetic Testing in Liver Disease: What to Order, in Whom, and When. <i>Clinics in Liver Disease</i> , 2017 , 21, 673-686	4.6	4
74	Ascites Neutrophil Gelatinase-Associated Lipocalin Identifies Spontaneous Bacterial Peritonitis and Predicts Mortality in Hospitalized Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 3487-3494	4.9	9
73	Selection of Candidates and Timing of Liver Transplantation 2017 , 1053-1064		
72	A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women. <i>Gastroenterology and Hepatology</i> , 2017 , 13, 154-163	0.7	1
71	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , 2017 , 16, 375-381	3.1	
70	Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 903-906.e1	6.9	25
69	Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. <i>Hepatology</i> , 2016 , 63, 319-33	11.2	209
68	Postpartum Laboratory Follow-up in Women With Hepatitis B in Massachusetts From 2007 to 2012. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, e60-4	3	8
67	Reply. <i>Hepatology</i> , 2016 , 64, 1824-1825	11.2	
66	Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. <i>Liver Transplantation</i> , 2016 , 22, 24-33	4.5	96
65	Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. <i>Hepatology</i> , 2016 , 63, 284-306	11.2	281
64	Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. <i>Hepatology</i> , 2016 , 63, 307-18	11.2	49
63	Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 122-132	18.8	52
62	HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016 , 36, 488-502	7.9	4
61	The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). <i>Therapeutic Advances in Gastroenterology</i> , 2015 , 8, 263-9	4.7	1
60	Postpartum care for mothers diagnosed with hepatitis B during pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2015 , 212, 365.e1-7	6.4	15
59	Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. <i>Gastroenterology</i> , 2015 , 148, 108-17	13.3	280

58	Liver transplantation for the referring physician. <i>Clinics in Liver Disease</i> , 2015 , 19, 135-53	4.6	4
57	Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. <i>Gastroenterology</i> , 2015 , 148, 100-107.e1	13.3	266
56	Reply: To PMID 24954365. <i>Hepatology</i> , 2015 , 61, 1439	11.2	
55	Reply: To PMID 24954365. <i>Hepatology</i> , 2015 , 62, 1328-9	11.2	
54	Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients. <i>Clinical and Translational Gastroenterology</i> , 2015 , 6, e74	4.2	11
53	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015 , 149, 649-59	13.3	622
52	Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL). <i>Journal of Hepatology</i> , 2015 , 62, 346-53	13.4	62
51	Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. <i>Hepatology</i> , 2014 , 59, 1144-65	11.2	502
50	Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. <i>Hepatology</i> , 2014 , 60, 1957-62	11.2	90
49	Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. <i>Hepatology</i> , 2014 , 59, 1073-83	11.2	101
48	An interferon-free antiviral regimen for HCV after liver transplantation. <i>New England Journal of Medicine</i> , 2014 , 371, 2375-82	59.2	335
47	Steroid use in acute liver failure. <i>Hepatology</i> , 2014 , 59, 612-21	11.2	122
46	Reply: To PMID 23929808. <i>Hepatology</i> , 2014 , 60, 1448	11.2	
45	Predictors of donor follow-up after living donor liver transplantation. <i>Liver Transplantation</i> , 2014 , 20, 967-76	4.5	8
44	A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. <i>Journal of Hepatology</i> , 2014 , 61, 508-14	13.4	68
43	A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. <i>Hepatology</i> , 2013 , 57, 1752-62	11.2	97
42	Hepatitis C viral infection after liver transplantation. <i>Clinical Liver Disease</i> , 2012 , 1, 73-76	2.2	
41	Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. <i>Journal of Hepatology</i> , 2012 , 57, 953-9	13.4	59

40	Hepatitis B and Liver Transplantation: Update in Management before and after Transplantation. <i>Current Hepatitis Reports</i> , 2011 , 10, 255-261		
39	Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. <i>Liver Transplantation</i> , 2011 , 17, 409-17	4.5	40
38	Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. <i>Hepatology</i> , 2011 , 54, 91-100	11.2	155
37	Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. <i>Hepatology</i> , 2011 , 54, 1313-21	11.2	100
36	Obesity and microvascular invasion in hepatocellular carcinoma. <i>Cancer Investigation</i> , 2010 , 28, 1063-9	2.1	20
35	Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. <i>Cancer</i> , 2010 , 116, 1801-9	6.4	49
34	Sorafenib: where do we go from here?. <i>Hepatology</i> , 2010 , 52, 360-9	11.2	80
33	Diagnostic utility of chromosome 17 and p16 abnormalities in fluorescence in situ hybridization tests in primary sclerosing cholangitis. <i>Hepatology</i> , 2010 , 52, 393-4; author reply 394-5	11.2	
32	Health-related quality of life and survival in liver transplant candidates. <i>Liver Transplantation</i> , 2010 , 16, 238-45	4.5	26
31	Current and emerging therapies for chronic hepatitis B: a review of selected presentations from the 2010 meeting of the European association for the study of the liver april 14-18, 2010 vienna, austria. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 1-8	0.7	
30	Viral hepatitis and renal failure. <i>Current Hepatitis Reports</i> , 2009 , 8, 119-126		
29	Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. <i>Liver International</i> , 2009 , 29, 1178-83	7.9	2
28	Pathophysiologic basis for the medical management of portal hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 453-67	4	1
27	Plasma levels of S100A4 in portopulmonary hypertension. <i>Biomarkers</i> , 2009 , 14, 156-60	2.6	7
26	Serotonin transporter polymorphisms in patients with portopulmonary hypertension. <i>Chest</i> , 2009 , 135, 1470-1475	5.3	34
25	Thrombocytopenia associated with chronic liver disease. <i>Journal of Hepatology</i> , 2008 , 48, 1000-7	13.4	383
24	The risk of hepatocellular carcinoma in patients with previous malignancy. <i>Cancer Investigation</i> , 2008 , 26, 511-5	2.1	
23	Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation. <i>Liver Transplantation</i> , 2008 , 14, 1357-65	4.5	22

22	WIN-R revisited: Response to editorial. <i>Hepatology</i> , 2008 , 47, 1427	11.2	
21	Clinical risk factors for portopulmonary hypertension. <i>Hepatology</i> , 2008 , 48, 196-203	11.2	189
20	Improvement in survival associated with adult-to-adult living donor liver transplantation. <i>Gastroenterology</i> , 2007 , 133, 1806-13	13.3	167
19	Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. <i>Hepatology</i> , 2007 , 46, 982-90	11.2	65
18	Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. <i>Hepatology</i> , 2007 , 46, 971-81	11.2	256
17	Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. <i>Liver Transplantation</i> , 2007 , 13, 122-9	4.5	103
16	Discovery of diffuse biliary microhamartomas during liver procurement. <i>Liver Transplantation</i> , 2007 , 13, 1470-1	4.5	3
15	Customizing treatment to patient populations. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007 , 4 Suppl 1, S3-9		5
14	Asymptomatic liver mass. <i>Gastroenterology</i> , 2006 , 131, 619-23	13.3	5
13	Role of the Independent Donor Advocacy Team in Ethical Decision Making. <i>Progress in Transplantation</i> , 2005 , 15, 298-302	1.1	11
12	Hepatitis C and liver transplantation. <i>Nature</i> , 2005 , 436, 973-8	50.4	292
11	The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. <i>American Journal of Transplantation</i> , 2005 , 5, 203-4	8.7	80
10	Predictors of candidate maturation among potential living donors. <i>American Journal of Transplantation</i> , 2005 , 5, 2549-54	8.7	12
9	One-year morbidity after donor right hepatectomy. <i>Liver Transplantation</i> , 2004 , 10, 1428-31	4.5	50
8	A survey of liver transplantation from living adult donors in the United States. <i>New England Journal of Medicine</i> , 2003 , 348, 818-25	59.2	399
7	Prevalence of HBV precore/core promoter variants in the United States. <i>Hepatology</i> , 2003 , 38, 619-28	11.2	166
6	Clinical and ethnic differences in candidates listed for liver transplantation with and without potential living donors. <i>Liver Transplantation</i> , 2003 , 9, 254-9	4.5	25
5	Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. <i>Liver Transplantation</i> , 2003 , 9, 1028-35	4.5	98

4	Scope of worldwide hepatitis C problem. <i>Liver Transplantation</i> , 2003 , 9, S10-3	4.5	111
3	Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. <i>Liver Transplantation</i> , 2002 , 8, 278-84	4.5	164
2	Should patients with chronic hepatitis C who have normal ALT levels be treated?. <i>Current Gastroenterology Reports</i> , 2001 , 3, 49-53	5	4
1	HCV and Liver Transplantation. <i>Current Hepatology Reports</i> , 1	1	